<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659112473172</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659112473172</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Is hyperoxaemia helping or hurting patients during extracorporeal membrane oxygenation? Review of a complex problem</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hayes</surname><given-names>RA</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Shekar</surname><given-names>K</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Fraser</surname><given-names>JF</given-names></name>
</contrib>
<aff id="aff1-0267659112473172">Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Brisbane, Queensland, Australia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0267659112473172">R A Hayes Critical Care Research Group Adult Intensive Care Services The Prince Charles Hospital Rode Road Chermside Queensland Australia 4032 Email: <email>rylan.hayes@bigpond.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>3</issue>
<fpage>184</fpage>
<lpage>193</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Extracorporeal membrane oxygenation (ECMO) facilitates organ support in patients with refractory cardiorespiratory failure whilst disease-modifying treatments can be administered. Improvements to the ECMO process have resulted in its increased utilisation. However, iatrogenic injuries remain, with bleeding and thrombosis the most significant concerns. Many factors contribute to the formation of thrombi, with the hyperoxaemia experienced during ECMO a potential contributor. Outside of ECMO, emerging evidence associates hyperoxaemia with increased mortality. Currently, no universal definition of hyperoxaemia exists, a gap in clinical standards that may impact patient outcomes. Hyperoxaemia has the potential to induce platelet activation, aggregation and, subsequently, thrombosis through markedly increasing the production of reactive oxygen species. There are minimal data in the current literature that explore the relationship between ECMO-induced hyperoxaemia and the production of reactive oxygen species – a putative link towards pathology. Furthermore, there is limited research directly linking hyperoxaemia and platelet activation. These are areas that warrant investigation as definitive data regarding the nascence of these pathological processes may delineate and define the relative risk of supranormal oxygen tension. These data could then assist in defining optimal oxygenation practice, reducing the risks associated with extracorporeal support.</p>
</abstract>
<kwd-group>
<kwd>cardiorespiratory failure</kwd>
<kwd>extracorporeal membrane oxygenation</kwd>
<kwd>hyperoxaemia</kwd>
<kwd>platelet activation</kwd>
<kwd>reactive oxygen species</kwd>
<kwd>thrombosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0267659112473172" sec-type="intro">
<title>Introduction</title>
<p>Data continue to accumulate which indicate that extracorporeal membrane oxygenation (ECMO) may salvage patients who might otherwise succumb to refractory cardiorespiratory failure.<sup><xref ref-type="bibr" rid="bibr1-0267659112473172">1</xref>,<xref ref-type="bibr" rid="bibr2-0267659112473172">2</xref></sup> Whilst ECMO may be associated with improved patient outcomes by supporting the patient – allowing time for therapeutic modalities to treat the culprit illness – survival rates are variable, depending on the indication and may be as low as 30% in cardiopulmonary resuscitation.<sup><xref ref-type="bibr" rid="bibr2-0267659112473172">2</xref></sup> These figures are clearly not ideal and demonstrate the need for further improvement of the process to both prevent iatrogenic injury and allow for better management of clinical sequelae. The indication for ECMO has historically focused around the critical care of cardiorespiratory patients,<sup><xref ref-type="bibr" rid="bibr3-0267659112473172">3</xref>,<xref ref-type="bibr" rid="bibr4-0267659112473172">4</xref></sup> although additional indications are becoming more common as the process is improved.<sup><xref ref-type="bibr" rid="bibr2-0267659112473172">2</xref>,<xref ref-type="bibr" rid="bibr3-0267659112473172">3</xref>,<xref ref-type="bibr" rid="bibr5-0267659112473172">5</xref><xref ref-type="bibr" rid="bibr6-0267659112473172"/><xref ref-type="bibr" rid="bibr7-0267659112473172"/>-<xref ref-type="bibr" rid="bibr8-0267659112473172">8</xref></sup> Its use, however, is known to be an imperfect substitute for the normal physiology and numerous adverse effects are recognised. Most significantly, these complications include thrombi formation, haemorrhages, infections, neurological events<sup><xref ref-type="bibr" rid="bibr2-0267659112473172">2</xref>,<xref ref-type="bibr" rid="bibr3-0267659112473172">3</xref>,<xref ref-type="bibr" rid="bibr6-0267659112473172">6</xref>,<xref ref-type="bibr" rid="bibr8-0267659112473172">8</xref><xref ref-type="bibr" rid="bibr9-0267659112473172"/>-<xref ref-type="bibr" rid="bibr10-0267659112473172">10</xref></sup> and limb ischaemia.<sup><xref ref-type="bibr" rid="bibr3-0267659112473172">3</xref></sup> A more comprehensive understanding of the pathophysiological patterns associated with ECMO would enable clinicians to predict, treat and ameliorate the clinical sequelae.</p>
<p>Many of these complications are assumed to result from the introduction of a foreign surface in the form of the ECMO circuit,<sup><xref ref-type="bibr" rid="bibr4-0267659112473172">4</xref>,<xref ref-type="bibr" rid="bibr11-0267659112473172">11</xref></sup> but there is also likely to be a complicated interplay of multiple contributing factors. One such factor may be the supranormal oxygen tensions witnessed during ECMO. It is unclear the extent to which 100% oxygen is detrimental to normal homeostasis, which has evolved in the milieu of 21% FiO<sub>2</sub>. The resulting hyperoxaemia may contribute to the development of adverse effects during ECMO. Despite these concerns, research into ECMO-induced hyperoxaemic damage is largely non-existent. Specifically, the effect of hyperoxaemia on the coagulation functions of platelets and neutrophils is entirely absent. This is even more surprising when it is considered that patients on ECMO will frequently have altered thrombophilicity, either through the acute phase process associated with the disease that necessitated the institution of ECMO or the therapeutics necessary to reverse this process.<sup><xref ref-type="bibr" rid="bibr11-0267659112473172">11</xref></sup> Ultimately, the formation of thromboses around cannulae is a significant clinical concern during ECMO and is the result of numerous factors which alter normal homeostasis. Although not definitive, the potential contribution of hyperoxaemia as one of these many factors warrants further consideration and subsequent investigation.</p>
</sec>
<sec id="section2-0267659112473172">
<title>What is hyperoxaemia?</title>
<p>There is no universal definition of what truly constitutes hyperoxaemia. This is clearly a hindrance in determining its effect if the scientific community cannot define it. A number of studies have suggested a number of definitions (<xref ref-type="table" rid="table1-0267659112473172">Table 1</xref>). The value used to define the presence of hyperoxaemia ranged from a P<sub>a</sub>O<sub>2</sub>&gt;100 mmHg in a study by Klinger et al.<sup><xref ref-type="bibr" rid="bibr12-0267659112473172">12</xref></sup> to a P<sub>a</sub>O<sub>2</sub>&gt;487 mmHg by Davis et al.<sup><xref ref-type="bibr" rid="bibr13-0267659112473172">13</xref></sup> This demonstrates both the range and variability of values used to define hyperoxaemia. Whilst a P<sub>a</sub>O<sub>2</sub>&gt;300 mmHg is the most commonly used value, it is by no means universally accepted. Furthermore, the definition of hyperoxaemia appears to be a largely arbitrary measure made by individual authors. Few studies use clinical reasoning to justify their chosen value, with only Bellomo et al. and Davis et al. offering justification for their use of a P<sub>a</sub>O<sub>2</sub>&gt;400 mmHg and a P<sub>a</sub>O<sub>2</sub>&gt;487 mmHg, respectively.<sup><xref ref-type="bibr" rid="bibr13-0267659112473172">13</xref>,<xref ref-type="bibr" rid="bibr14-0267659112473172">14</xref></sup></p>
<table-wrap id="table1-0267659112473172" position="float">
<label>Table 1.</label>
<caption><p>Inconsistency of values used to define hyperoxaemia in the current literature.</p></caption>
<graphic alternate-form-of="table1-0267659112473172" xlink:href="10.1177_0267659112473172-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">P<sub>a</sub>O<sub>2</sub> Value (mmHg)</th>
<th align="left">Author’s Definition</th>
<th align="left">Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;100</td>
<td>Moderate Hyperoxaemia</td>
<td>Klinger et al.<sup><xref ref-type="bibr" rid="bibr12-0267659112473172">12</xref></sup></td>
</tr>
<tr>
<td>150-250</td>
<td>Hyperoxaemia</td>
<td>Schultz et al.<sup><xref ref-type="bibr" rid="bibr33-0267659112473172">33</xref></sup></td>
</tr>
<tr>
<td>&gt;180</td>
<td>Hyperoxaemia</td>
<td>Toraman et al.<sup><xref ref-type="bibr" rid="bibr34-0267659112473172">34</xref></sup></td>
</tr>
<tr>
<td>&gt;185</td>
<td>Hyperoxaemia</td>
<td>Joachimsson et al.<sup><xref ref-type="bibr" rid="bibr19-0267659112473172">19</xref></sup></td>
</tr>
<tr>
<td>&gt;200</td>
<td>Severe Hyperoxaemia</td>
<td>Klinger et al.<sup><xref ref-type="bibr" rid="bibr12-0267659112473172">12</xref></sup></td>
</tr>
<tr>
<td>&gt;300</td>
<td>Hyperoxaemia</td>
<td>Bellomo et al.,<sup><xref ref-type="bibr" rid="bibr14-0267659112473172">14</xref></sup> Ferguson et al.,<sup><xref ref-type="bibr" rid="bibr23-0267659112473172">23</xref></sup> Kilgannon et al.,<sup><xref ref-type="bibr" rid="bibr20-0267659112473172">20</xref></sup> Neumar et al.<sup><xref ref-type="bibr" rid="bibr38-0267659112473172">38</xref></sup></td>
</tr>
<tr>
<td>&gt;400</td>
<td>Hyperoxaemia (redefined after analysis)</td>
<td>Bellomo et al.<sup><xref ref-type="bibr" rid="bibr14-0267659112473172">14</xref></sup></td>
</tr>
<tr>
<td>&gt;487</td>
<td>Extreme Hyperoxaemia</td>
<td>Davis et al.<sup><xref ref-type="bibr" rid="bibr13-0267659112473172">13</xref></sup></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-0267659112473172">
<title>Hyperoxia during ECMO</title>
<p>The typical ECMO circuit and configurations used are described in <xref ref-type="fig" rid="fig1-0267659112473172">Figure 1</xref>. The highest partial pressures of oxygen are experienced in the circuit distal to the oxygenator. After mixing upon return to the venous circulation (right atrium in venovenous (VV) ECMO), the magnitude of hyperoxaemia is reduced, leading to at least moderate hyperoxaemia in the pulmonary circulation. The major determinants of the degree of pulmonary arterial hyperoxaemia include – the percentage cardiac output captured for ECMO (i.e. flow rate), the integrity of the oxygenator, the percentage inspired oxygen concentration settings on the ventilator and ECMO circuit, the presence of a second oxygenator in the circuit, the use of an additional venous cannula for access, the venous capacitance and return, the intravascular volume, the haemoglobin, the temperature, the sedation and the use of neuromuscular paralysis. The native lungs, essentially, act as shunts in this setting and the systemic oxygen tensions are eventually determined by the degree of shunting that occurs for a given concentration of oxygen delivered, both through the native lungs via mechanical ventilation and through ECMO.</p>
<fig id="fig1-0267659112473172" position="float">
<label>Figure 1.</label>
<caption><p>Diagrammatic portrayal of different cannulation configurations used for extracorporeal membrane oxygenation (ECMO). In both configurations, deoxygenated blood (blue line) is removed from the venous circulation. In venoarterial (VA) ECMO, oxygenated blood (red line) is returned to arterial circulation. Conversely, in venovenous (VV) ECMO the return is made to the venous system<sup><xref ref-type="bibr" rid="bibr16-0267659112473172">16</xref></sup> (reproduced with permission from Elsevier).</p></caption>
<graphic xlink:href="10.1177_0267659112473172-fig1.tif"/>
</fig>
<p>In venoarterial ECMO, the oxygenated blood is returned directly to the arterial side of the circulation, either at the level of the distal descending aorta or the ascending aorta, depending on the peripheral or central cannulation strategy.<sup><xref ref-type="bibr" rid="bibr15-0267659112473172">15</xref>,<xref ref-type="bibr" rid="bibr16-0267659112473172">16</xref></sup> The use of a peripheral arterial (femoral artery) cannula for return predisposes the patients to lower body hyperoxia and risks upper body hypoxaemia. This is especially a concern when the native lung function is compromised and when cardiac functions start to recover.<sup><xref ref-type="bibr" rid="bibr17-0267659112473172">17</xref></sup></p>
<p>Thus, ECMO can expose vital organs, such as the liver, the kidneys, the gastrointestinal tract and the lungs to supranormal oxygen tensions, the consequences of which are currently unclear and clearly merit further investigation.<sup><xref ref-type="bibr" rid="bibr4-0267659112473172">4</xref></sup></p>
</sec>
<sec id="section4-0267659112473172">
<title>Can hyperoxaemia cause harm?</title>
<p>A range of studies, covering several different disease processes, have demonstrated results supporting the danger of hyperoxaemia.<sup><xref ref-type="bibr" rid="bibr12-0267659112473172">12</xref>,<xref ref-type="bibr" rid="bibr13-0267659112473172">13</xref>,<xref ref-type="bibr" rid="bibr18-0267659112473172">18</xref><xref ref-type="bibr" rid="bibr19-0267659112473172"/><xref ref-type="bibr" rid="bibr20-0267659112473172"/><xref ref-type="bibr" rid="bibr21-0267659112473172"/><xref ref-type="bibr" rid="bibr22-0267659112473172"/>-<xref ref-type="bibr" rid="bibr23-0267659112473172">23</xref></sup> Kilgannon et al.<sup><xref ref-type="bibr" rid="bibr19-0267659112473172">19</xref></sup> demonstrated that hyperoxaemia is associated with increased intensive care unit mortality following resuscitation from cardiac arrest. This finding has been proven consistent in children, as demonstrated by Ferguson et al.<sup><xref ref-type="bibr" rid="bibr22-0267659112473172">22</xref></sup> in a similar cohort study. In the setting of traumatic brain injury, Davis et al.<sup><xref ref-type="bibr" rid="bibr13-0267659112473172">13</xref></sup> showed an increase in mortality with a P<sub>a</sub>O<sub>2</sub>&gt;487 mmHg while Brenner et al.<sup><xref ref-type="bibr" rid="bibr23-0267659112473172">23</xref></sup> found that mortality increased above 200 mmHg. Klinger et al.<sup><xref ref-type="bibr" rid="bibr12-0267659112473172">12</xref></sup> demonstrated that asphyxiated neonates exposed to hyperoxaemia were at increased risk of adverse effects (including death) after 24 months. Tsangaris et al.<sup><xref ref-type="bibr" rid="bibr20-0267659112473172">20</xref></sup> found erythropoietin (EPO) production to be inhibited by hyperoxaemia, even in anaemic patients, possibly exacerbating the anaemia frequently observed in long-term intensive care patients. Joachimsson et al.<sup><xref ref-type="bibr" rid="bibr18-0267659112473172">18</xref></sup> showed that, during cardiopulmonary bypass (CPB), oxygen delivery and uptake to skeletal muscle is reduced. This was believed to be due to a microcirculatory response promoting vasoconstriction. If this response is consistent for other organs, especially the brain<sup><xref ref-type="bibr" rid="bibr23-0267659112473172">23</xref></sup> and heart, it may offer some explanation as to the negative effects of hyperoxaemia. Further explanations for hyperoxaemic damage include the production of reactive oxygen species (ROS) and reactive nitrogen species, leading to cellular dysfunction or necrosis.<sup><xref ref-type="bibr" rid="bibr23-0267659112473172">23</xref><xref ref-type="bibr" rid="bibr24-0267659112473172"/>-<xref ref-type="bibr" rid="bibr25-0267659112473172">25</xref></sup> It should be noted that none of these studies involved ECMO and the hyperoxaemia was recorded from peripheral arterial blood samples. This pattern of hyperoxaemia is unexpected in VV-ECMO where the highest partial pressures are experienced within the circuit. Nevertheless, the findings raise concerns regarding the safety of hyperoxaemia.</p>
<p>There is also some evidence that hyperoxaemia may improve outcomes in some scenarios.<sup><xref ref-type="bibr" rid="bibr26-0267659112473172">26</xref><xref ref-type="bibr" rid="bibr27-0267659112473172"/>-<xref ref-type="bibr" rid="bibr28-0267659112473172">28</xref></sup> Following acute myocardial infarction, Bartorelli et al.<sup><xref ref-type="bibr" rid="bibr26-0267659112473172">26</xref></sup> found decreased infarct size and improved left ventricular function when angioplasty reperfusion was used with adjunctive hyperoxia. Both hyperbaric oxygen therapy and, more practically, aqueous oxygen delivery showed these benefits.<sup><xref ref-type="bibr" rid="bibr26-0267659112473172">26</xref></sup> Larger, randomised trials are underway to investigate these findings.<sup><xref ref-type="bibr" rid="bibr26-0267659112473172">26</xref>,<xref ref-type="bibr" rid="bibr29-0267659112473172">29</xref></sup> There have also been benefits observed following cerebral ischaemia in rats, where arterial hyperoxaemia may provide a degree of neuroprotection.<sup><xref ref-type="bibr" rid="bibr27-0267659112473172">27</xref>,<xref ref-type="bibr" rid="bibr28-0267659112473172">28</xref>,<xref ref-type="bibr" rid="bibr30-0267659112473172">30</xref></sup></p>
<p>Although evidence is variable and at times conflicting, these results raise potential dangers of hyperoxaemia in a range of clinical settings and convey uncertainty as to the implications and the need for further assessment. Additional research into the effects of hyperoxaemia, both benefits and detriments, is warranted to establish best practice for oxygenation.<sup><xref ref-type="bibr" rid="bibr31-0267659112473172">31</xref></sup> Additionally, in order to improve patient monitoring and outcomes, developing a universal standard for hyperoxaemia would need to be considered. This would have implications not only for ECMO, but any area of medicine which involves supranormal oxygen tensions – such as cardiac surgery, where patients on CPB are routinely exposed to periods of hyperoxaemia.<sup><xref ref-type="bibr" rid="bibr18-0267659112473172">18</xref>,<xref ref-type="bibr" rid="bibr32-0267659112473172">32</xref>,<xref ref-type="bibr" rid="bibr33-0267659112473172">33</xref></sup> As such, any standard would need to be assessed for appropriateness from the perspective of numerous specialties and physiological systems.</p>
</sec>
<sec id="section5-0267659112473172">
<title>Production of reactive oxygen species</title>
<p>A significant effect of hyperoxaemia is the subsequent increase in production of ROS and their associated oxidative damage.<sup><xref ref-type="bibr" rid="bibr24-0267659112473172">24</xref>,<xref ref-type="bibr" rid="bibr25-0267659112473172">25</xref>,<xref ref-type="bibr" rid="bibr28-0267659112473172">28</xref></sup> ROS are free radicals, negatively charged molecules containing an unpaired electron which can cause altered function on a molecular level. They cause this damage in the process of losing the unpaired electron in their outer shell by oxidising with DNA, proteins and lipids.<sup><xref ref-type="bibr" rid="bibr34-0267659112473172">34</xref></sup> Alterations to these macromolecules can cause abnormal gene expression and/or impaired cellular functioning, leading to pathology. While production of ROS is physiological and necessary for energy production and innate immunity, the contribution of ROS is extensively established in the pathogenesis of numerous diseases.<sup><xref ref-type="bibr" rid="bibr34-0267659112473172">34</xref></sup> Many of these diseases are associated with aging processes, such as diabetes, cancers and neurodegenerative disorders.<sup><xref ref-type="bibr" rid="bibr34-0267659112473172">34</xref><xref ref-type="bibr" rid="bibr35-0267659112473172"/>-<xref ref-type="bibr" rid="bibr36-0267659112473172">36</xref></sup> With such numerous related pathologies, it is unsurprising that an increase in the production of ROS during hyperoxaemia is well documented in the literature.<sup><xref ref-type="bibr" rid="bibr25-0267659112473172">25</xref>,<xref ref-type="bibr" rid="bibr28-0267659112473172">28</xref>,<xref ref-type="bibr" rid="bibr37-0267659112473172">37</xref></sup> Moreover, the critically ill patient on ECMO is not only at a high risk of hyperoxaemia and related insults by virtue of the illness which has necessitated institution of ECMO, but also by the pathophysiological changes that occur during ECMO. Subsequently, ROS are a logical link between ECMO-induced hyperoxaemia and impaired physiological function (<xref ref-type="fig" rid="fig2-0267659112473172">Figure 2</xref>). Therefore, the effect of ROS on platelets, neutrophils and factors of coagulation should be thoroughly investigated to determine the clinical significance.</p>
<fig id="fig2-0267659112473172" position="float">
<label>Figure 2.</label>
<caption><p>ECMO; extracorporeal membrane oxygenation. ROS; reactive oxygen species. Proposed effect of hyperoxaemia on clotting function, demonstrating the complex relationship between platelet and neutrophil function. Also shown are the effects of the non-endothelialised ECMO circuit, transfusion-related oxidative stress and an already inflamed patient further contributing to the activation of platelets and neutrophils.</p></caption>
<graphic xlink:href="10.1177_0267659112473172-fig2.tif"/>
</fig>
<p>The majority of studies assessing ROS formation address hypoxaemia-hyperoxaemia and, while ECMO can be indicated in normoxaemic patients, the majority of patients are likely to have suffered a period of hypoxaemia prior to the initiation of ECMO, such as during acute respiratory distress syndrome (ARDS). This is evident in a study by Garcia et al. that assessed patients with chronic lung disease, of whom 5/10 had a P<sub>a</sub>O<sub>2</sub>&lt;60 mmHg before ECMO was commenced.<sup><xref ref-type="bibr" rid="bibr5-0267659112473172">5</xref></sup> While any hyperoxaemia evokes excess ROS production, this is further exaggerated following hypoxia because of post-ischaemic mitochondrial electron transport chain dysfunction.<sup><xref ref-type="bibr" rid="bibr37-0267659112473172">37</xref></sup></p>
<p>It should be emphasised that oxidative stress may be induced by numerous mechanisms in addition to hyperoxaemia. In the setting of ECMO, the possibility of transfusion-related oxidative stress and trace element wasting exists, compounding the damage to an already vulnerable patient. Patients on ECMO commonly receive blood product transfusions,<sup><xref ref-type="bibr" rid="bibr38-0267659112473172">38</xref></sup> which can contribute to the overall oxidative stress, a phenomenon confirmed by emerging data.<sup><xref ref-type="bibr" rid="bibr39-0267659112473172">39</xref></sup> Additionally, in vitro studies suggest that the ECMO circuit may sequester trace elements and other bioactive substances integral to the patient’s innate antioxidant mechanisms.<sup><xref ref-type="bibr" rid="bibr40-0267659112473172">40</xref></sup> However, loss of these trace elements was not associated with reduced production of antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidise<sup><xref ref-type="bibr" rid="bibr41-0267659112473172">41</xref>,<xref ref-type="bibr" rid="bibr42-0267659112473172">42</xref></sup> and the clinical consequences are currently unclear.<sup><xref ref-type="bibr" rid="bibr40-0267659112473172">40</xref></sup></p>
</sec>
<sec id="section6-0267659112473172">
<title>Hyperoxaemia and neutrophils</title>
<p>Combined with the extensive presence of neutrophils in the lungs – exacerbated by pulmonary sequestration in acute lung injury (ALI) and hyperoxic pulmonary neutrophil transmigration – any effect of hyperoxaemia on neutrophil function will have major implications.<sup><xref ref-type="bibr" rid="bibr25-0267659112473172">25</xref>,<xref ref-type="bibr" rid="bibr43-0267659112473172">43</xref>,<xref ref-type="bibr" rid="bibr44-0267659112473172">44</xref></sup> This was observed clinically during the 2009 H1N1 pandemic. Patients who received VV-ECMO for severe respiratory failure had a typical progression of chest x-ray changes. These were characterised by a rapid and complete white-out of the lungs, with dense consolidation (<xref ref-type="fig" rid="fig3-0267659112473172">Figure 3</xref>). Clinicians attributed this to a multifactorial process with key factors, including progression of the ARDS and lung protective ventilation (very low tidal volume ventilation and diminution of positive end-expiratory pressure (PEEP)), resulting in atelectrauma. However, many of these patients actually received high PEEP,<sup><xref ref-type="bibr" rid="bibr45-0267659112473172">45</xref>,<xref ref-type="bibr" rid="bibr46-0267659112473172">46</xref></sup> raising the possibility for some degree of contribution from other mechanisms, such as hyperoxia and neutrophil-related lung damage. Although not established, the potential contribution of ECMO to the observed clinical changes needs consideration.</p>
<fig id="fig3-0267659112473172" position="float">
<label>Figure 3.</label>
<caption><p>Typical chest x-ray changes observed in patients who receive venovenous extracorporeal membrane oxygenation (ECMO) for severe respiratory failure. The x-ray before initiation of ECMO (a) progresses to complete ‘white-out’ of the lung fields accompanied by dense consolidation (6 hours after commencement) (b). The development of consolidation is likely due to a number of factors, including progression of lung injury, mechanical ventilation and the added insult of ECMO.</p></caption>
<graphic xlink:href="10.1177_0267659112473172-fig3.tif"/>
</fig>
<p>The effect of hyperoxaemia on neutrophils is a convoluted relationship. On the one hand, neutrophils are extremely potent sources of ROS during reperfusion injury. As such, they contribute extensively to the deleterious effects of hyperoxaemia.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref></sup> On the other hand, they themselves are activated by ROS, even under normoxaemic conditions, as a physiological process.<sup><xref ref-type="bibr" rid="bibr34-0267659112473172">34</xref>,<xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref><xref ref-type="bibr" rid="bibr48-0267659112473172"/>-<xref ref-type="bibr" rid="bibr49-0267659112473172">49</xref></sup> However, this ability to activate rapidly makes them susceptible to unnecessary and unregulated activation during periods of hyperoxaemia. It is possible that the neutrophils’ own autoregulatory properties are overwhelmed by the non-physiological and prolonged hyperoxia. Their pathological activation has two broad effects, namely, direct interaction between neutrophils with other cells and indirect signalling via the production of pro-inflammatory cytokines.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref></sup> Directly, the activity of neutrophil adhesion is markedly increased.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref></sup> Subsequently, it has been shown that the free radical-induced release of 8-iso-PGF2a from neutrophils stimulates their own adhesion to fibrinogen.<sup><xref ref-type="bibr" rid="bibr48-0267659112473172">48</xref></sup> Additional to fibrinogen adhesion, activated neutrophils adhere more readily to damaged endothelium, forming a blockage in the microvasculature – along with activated platelets.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref></sup> Indirectly, activation of neutrophils evokes the production and/or release of a host of chemical mediators.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref></sup> The proinflammatory cytokine TNFα is one such mediator produced and it exhibits a wide range of effects on both neutrophil and platelet function.<sup><xref ref-type="bibr" rid="bibr47-0267659112473172">47</xref>,<xref ref-type="bibr" rid="bibr48-0267659112473172">48</xref>,<xref ref-type="bibr" rid="bibr50-0267659112473172">50</xref>,<xref ref-type="bibr" rid="bibr51-0267659112473172">51</xref></sup> It stimulates the expression of adhesion molecules such as ICAM-1 on the endothelium, to which platelets and neutrophils bind. TNFα also acts on neutrophils to induce degranulation, a process that enhances oxidative stress and stimulates thromboxane production in platelets and neutrophils via the arachidonic acid pathway.<sup><xref ref-type="bibr" rid="bibr48-0267659112473172">48</xref>,<xref ref-type="bibr" rid="bibr50-0267659112473172">50</xref></sup> Interestingly, TNFα also enhances superoxide formation in platelets, subsequent to activation of the arachidonic acid pathway, in a dose-dependent fashion.<sup><xref ref-type="bibr" rid="bibr51-0267659112473172">51</xref></sup> Thus, TNFα further contributes to ROS formation through this secondary mechanism. Consequent to this activation-production cycle, it is possible that, under ECMO-induced hyperoxaemia, neutrophils become both a source of damaging ROS and a pathological target for these species – though such a relationship involving cytokines (especially TNFα and various interleukins) during ECMO is yet to be established. The limited data available in this area are largely inconsistent. Some studies report no change in some interleukins, but an increase in others, while other studies showed an opposing pattern of change.<sup><xref ref-type="bibr" rid="bibr52-0267659112473172">52</xref><xref ref-type="bibr" rid="bibr53-0267659112473172"/><xref ref-type="bibr" rid="bibr54-0267659112473172"/>-<xref ref-type="bibr" rid="bibr55-0267659112473172">55</xref></sup> In many other forms of lung injury, such as transfusion-related acute lung injury,<sup><xref ref-type="bibr" rid="bibr56-0267659112473172">56</xref>,<xref ref-type="bibr" rid="bibr57-0267659112473172">57</xref></sup> neutrophils play a significant causative role and whether hyperoxaemia contributes to their activation remains subject to future research.</p>
</sec>
<sec id="section7-0267659112473172">
<title>Hyperoxaemia and platelets</title>
<p>In anoxia-reoxygenation, production of ROS in platelets via the arachidonic acid pathway is mediated by NOX2 activation and, consequently, NADPH oxidase.<sup><xref ref-type="bibr" rid="bibr50-0267659112473172">50</xref>,<xref ref-type="bibr" rid="bibr58-0267659112473172">58</xref>,<xref ref-type="bibr" rid="bibr59-0267659112473172">59</xref></sup> This process ultimately produces thromboxane A2 and B2, which act on and activate platelets by inducing three distinct responses - conformational change, secretion and aggregation.<sup><xref ref-type="bibr" rid="bibr60-0267659112473172">60</xref>,<xref ref-type="bibr" rid="bibr61-0267659112473172">61</xref></sup> Though they are each a distinct process, conformational change and secretion predominantly function to increase aggregation and, thus, thrombosis. This occurs via binding to G-protein-coupled thromboxane receptors, triggering an increase in intracellular Ca<sub>2</sub><sup>+</sup> concentration, functioning to increase the thrombophilicity of the platelets.<sup><xref ref-type="bibr" rid="bibr62-0267659112473172">62</xref></sup> Additionally, very low concentrations of ROS are also shown to result in the activation of platelets.<sup><xref ref-type="bibr" rid="bibr63-0267659112473172">63</xref></sup> It is conceivable that hyperoxaemic conditions will amplify these effects, resulting in increased and more rapid activation.</p>
<p>The conformational change seen in platelets has three important features. The overall shape changes from a circulating discoid form to demonstrate a spherical, spiculated appearance.<sup><xref ref-type="bibr" rid="bibr64-0267659112473172">64</xref>,<xref ref-type="bibr" rid="bibr65-0267659112473172">65</xref></sup> Secondly, the formation of cytoskeletal cellular projections – lamellipodia and filopodia – assists with aggregation.<sup><xref ref-type="bibr" rid="bibr64-0267659112473172">64</xref></sup> Additional to these cytoskeletal changes, conformational changes to the surface receptors are seen. Most notably, the glycoprotein (GP) IIb/IIIa complex formed during this change is critically important in inducing fibrinogen binding.<sup><xref ref-type="bibr" rid="bibr65-0267659112473172">65</xref></sup> Platelets store a vast range of bioactive mediators which act on numerous cells following their release upon platelet activation.<sup><xref ref-type="bibr" rid="bibr66-0267659112473172">66</xref>,<xref ref-type="bibr" rid="bibr67-0267659112473172">67</xref></sup> The release occurs in two stages: granules succeeded by lysosomes.<sup><xref ref-type="bibr" rid="bibr66-0267659112473172">66</xref></sup> In addition to these secretions increasing platelet-platelet bonds, they also contain chemokines and coagulation factors to recruit and activate cells involved in forming a mature thrombus.<sup><xref ref-type="bibr" rid="bibr66-0267659112473172">66</xref></sup></p>
<p>Ultimately, pathological activation of platelets markedly increases the risk of thrombotic events, particularly within and around the circuit.<sup><xref ref-type="bibr" rid="bibr68-0267659112473172">68</xref></sup> Accordingly, this is carefully managed through continuous heparin infusion and monitored throughout ECMO through regular activated coagulation time (ACT) tests.<sup><xref ref-type="bibr" rid="bibr10-0267659112473172">10</xref>,<xref ref-type="bibr" rid="bibr11-0267659112473172">11</xref>,<xref ref-type="bibr" rid="bibr69-0267659112473172">69</xref>,<xref ref-type="bibr" rid="bibr70-0267659112473172">70</xref></sup> Heparin is indicated when the ACT is insufficient to prevent thrombus formation.<sup><xref ref-type="bibr" rid="bibr4-0267659112473172">4</xref>,<xref ref-type="bibr" rid="bibr11-0267659112473172">11</xref>,<xref ref-type="bibr" rid="bibr70-0267659112473172">70</xref></sup> Pathological platelet activation, however, also has a likely paradoxical effect – increased risk of haemorrhage.<sup><xref ref-type="bibr" rid="bibr69-0267659112473172">69</xref></sup> While these aggregations of platelets are more likely to form thrombi, such a widespread process also reduces the availability of platelets for physiological activation,<sup><xref ref-type="bibr" rid="bibr6-0267659112473172">6</xref></sup> effectively contributing to a vulnerable state with possible pre-existing thrombocytopenia. This obviously has serious implications and, along with heparin prophylaxis<sup><xref ref-type="bibr" rid="bibr67-0267659112473172">67</xref></sup> and thrombocytopenia resultant from the artificial membrane,<sup><xref ref-type="bibr" rid="bibr71-0267659112473172">71</xref></sup> may be one of numerous factors which are associated with an increased risk of haemorrhage during treatment with ECMO.</p>
</sec>
<sec id="section8-0267659112473172">
<title>Mitigating hyperoxaemia-induced platelet and neutrophil dysfunction during ECMO</title>
<p>When the innate mechanisms for dealing with oxidative stress become overwhelmed, supplementing these protective pathways may be beneficial. The addition of nitric oxide (NO) to the circuit, selenium supplementation and N-acetylcystine (NAC) administration are raised as options. It should be emphasised that the evidence for use of these is limited, questionable or conflicting. Nevertheless, they are presented as options to investigate in ex vivo and in vivo models, as well as clinical subjects receiving ECMO.</p>
<p>NO is a potent modulator of platelet function, capable of significantly inhibiting platelet aggregation.<sup><xref ref-type="bibr" rid="bibr72-0267659112473172">72</xref>,<xref ref-type="bibr" rid="bibr73-0267659112473172">73</xref></sup> In ARDS, this effect was seen without a prolongation of bleeding time,<sup><xref ref-type="bibr" rid="bibr72-0267659112473172">72</xref></sup> a relevant consideration owing to the risk of haemorrhage with ECMO. However, these benefits were not seen in a different study involving CPB patients.<sup><xref ref-type="bibr" rid="bibr73-0267659112473172">73</xref></sup> Another study during simulated ECMO failed to produce significant inhibition of platelet aggregation despite an observed 25% higher platelet count in the treatment group.<sup><xref ref-type="bibr" rid="bibr74-0267659112473172">74</xref></sup> Evidence, in the form of a 2010 Cochrane Review, recommends against inhaled NO in ALI or ARDS<sup><xref ref-type="bibr" rid="bibr75-0267659112473172">75</xref></sup> as survival is unchanged and its use may precipitate kidney function impairment.<sup><xref ref-type="bibr" rid="bibr76-0267659112473172">76</xref></sup> However, this review assessed NO during hypoxia rather than as an antioxidant. Additionally, it does not evaluate administration of NO into the ECMO circuit. Accordingly, further investigation is required to determine if it has a role in ECMO.</p>
<p>Although not a result of hyperoxaemia, selenium wasting may limit the production of selenium-requiring anti-oxidant enzymes, though the limited data appear to conflict this.<sup><xref ref-type="bibr" rid="bibr40-0267659112473172">40</xref></sup> If it were the case, the management of ROS produced during hyperoxaemia may be impaired.<sup><xref ref-type="bibr" rid="bibr40-0267659112473172">40</xref>,<xref ref-type="bibr" rid="bibr42-0267659112473172">42</xref></sup> Because selenium concentrations decrease in critically ill patients<sup><xref ref-type="bibr" rid="bibr77-0267659112473172">77</xref></sup> and there is evidence that supplementation reduces mortality in this setting,<sup><xref ref-type="bibr" rid="bibr78-0267659112473172">78</xref></sup> there may be a benefit with selenium supplementation during ECMO, though the biochemical plausibility behind this requires further investigation.<sup><xref ref-type="bibr" rid="bibr40-0267659112473172">40</xref></sup></p>
<p>NAC has shown benefit as an antioxidant in vivo and may be of use in reducing oxidative stress.<sup><xref ref-type="bibr" rid="bibr79-0267659112473172">79</xref></sup> Although not tested with ECMO, in vitro studies demonstrated decreased production of ROS by polymorphonuclear neutrophils with NAC administration.<sup><xref ref-type="bibr" rid="bibr80-0267659112473172">80</xref></sup> Considering pathological neutrophil activation is likely to be a significant source of ROS during ECMO, NAC may prove useful in preventing iatrogenic injury. Conflicting evidence exists, with studies showing that NAC offers no renal protection nor does it affect oxidative stress during coronary intervention.<sup><xref ref-type="bibr" rid="bibr81-0267659112473172">81</xref>,<xref ref-type="bibr" rid="bibr82-0267659112473172">82</xref></sup></p>
<p>Ultimately, the efficacy of these therapies is uncertain and there is currently no clear evidence to support their use in ECMO. Nevertheless, the expanding use of ECMO in critically ill patients warrants further investigation into adjunctive therapies. Furthermore, if hyperoxaemia is indeed a potent cause of adverse effects during ECMO, preventing this by limiting oxygenation may be a key route to reducing injury.</p>
</sec>
<sec id="section9-0267659112473172">
<title>Limitations and challenges to future research</title>
<p>While the focus of this article is hyperoxaemic damage, it is important to recognise that the activation of platelets and neutrophils also occurs through a multitude of factors, particularly evident in the critically ill patient.<sup><xref ref-type="bibr" rid="bibr83-0267659112473172">83</xref>,<xref ref-type="bibr" rid="bibr84-0267659112473172">84</xref></sup> Isolation and relative quantification of the circuit and patient factors may not be feasible in the critically ill patient receiving ECMO.</p>
<p>Aside from oxidative damage secondary to hyperoxaemia, pre-activated platelets and neutrophils are also activated by the non-endothelialised ECMO circuitry.<sup><xref ref-type="bibr" rid="bibr4-0267659112473172">4</xref>,<xref ref-type="bibr" rid="bibr85-0267659112473172">85</xref>,<xref ref-type="bibr" rid="bibr86-0267659112473172">86</xref></sup> The extensive naked surface area of the circuit causes an inflammatory response similar to a foreign body or pathogen, but on a much larger scale, consistent with the non-endothelialised surface seeing up to 7 L/min cardiac output passing across these membranes.<sup><xref ref-type="bibr" rid="bibr85-0267659112473172">85</xref></sup> Subsequent to the activation of platelets and neutrophils by the naked synthetic membrane and cannulae, inflammatory cytokines (most notably TNFα and interleukins) are released unregulated.<sup><xref ref-type="bibr" rid="bibr85-0267659112473172">85</xref></sup></p>
<p>Furthermore, the overall changes to the cytokine profile during ECMO are poorly understood and often inconsistent, an area that requires investigation. Additional to the foreign surface, the presence and function of ECMO cannulae disrupt the normal blood flow by producing areas of turbulent flow within the vessels, resulting in further predisposition to thromboses.<sup><xref ref-type="bibr" rid="bibr87-0267659112473172">87</xref></sup> While thromboses usually occur within and around the circuitry, a recent study by Shafii et al.<sup><xref ref-type="bibr" rid="bibr87-0267659112473172">87</xref></sup> found an increased incidence of upper limb deep vein thrombosis (DVT) ipsilateral to the VV-ECMO cannulae. This was thought to be from the turbulence as there are no other reported increases in DVT risk during ECMO. This turbulent flow, as well as the pressure difference within the ECMO pump, produces significant cellular trauma, further complicating the clinical picture and precipitating thrombosis.<sup><xref ref-type="bibr" rid="bibr88-0267659112473172">88</xref>,<xref ref-type="bibr" rid="bibr89-0267659112473172">89</xref></sup></p>
<p>The scenario and condition of the patient are also likely to be a major influence on both the damage of ECMO and the contribution of hyperoxaemia to the adverse effects. Prior to ECMO commencement, a patient’s age, necessitating pathology, haemodynamic stability, gas exchange functionality and current state of inflammation are all likely to affect how a patient responds to the institution of a secondary insult in ECMO. This ‘two-hit’ concept may complicate the investigation into the sequelae of ECMO damage as data may not be readily transferable due to the heterogeneity of patients requiring ECMO support.</p>
</sec>
<sec id="section10-0267659112473172">
<title>Experimental models to investigate hyperoxaemia</title>
<p>Owing to the range of contributing factors – physiological, pathological and therapeutic – it will be difficult to study the effects of hyperoxaemia on platelets in the clinical setting. An incremental approach that involves ex vivo and in vivo large animal models is desirable. Ex vivo models, can better control for the numerous variables related to critical illness.<sup><xref ref-type="bibr" rid="bibr90-0267659112473172">90</xref></sup> This controlled information would allow for comparison of platelet function studies between normoxaemic and hyperoxaemic conditions, demonstrating either the presence or absence of significant effects related to increasing oxygen tensions. Following this, animal models can be used to determine the clinical importance of these findings.<sup><xref ref-type="bibr" rid="bibr90-0267659112473172">90</xref></sup> Currently, our group has established a validated ovine model using VV-ECMO<sup><xref ref-type="bibr" rid="bibr90-0267659112473172">90</xref>,<xref ref-type="bibr" rid="bibr91-0267659112473172">91</xref></sup> and the opportunity to incorporate investigations into the effects of hyperoxaemia is readily available. The ovine model is also advantageous in allowing histological examinations to corroborate potential end-organ damage with blood sampling data.</p>
</sec>
<sec id="section11-0267659112473172" sec-type="conclusions">
<title>Conclusion</title>
<p>Emerging data suggest hyperoxaemia has the potential for wide-reaching consequences, possibly via the damage caused through ROS. When focused on coagulation, these effects demonstrate a complex degree of interrelationship involving, notably, neutrophils and platelets (<xref ref-type="fig" rid="fig2-0267659112473172">Figure 2</xref>). While the literature describing these effects does not consider ECMO-induced hyperoxaemia, it is taken from largely congruent techniques (such as CPB). As such, the possibility that ECMO-induced hyperoxaemia will induce pathological ROS production has been presented. If this is the case, this, in turn, could see platelet and neutrophil activation, leading to an overall thrombophilic state in an already vulnerable patient. The relationship between degree of supranormal oxygen tension and platelet activation certainly needs to be further investigated. Whether hyperoxaemic platelet activation is dose-dependant or based on a required minimum degree of hyperoxaemia is currently unclear. These issues can be best investigated using a combination of ex vivo and animal models, with the goal to improve the understanding of the changes observed during ECMO and, subsequently, optimise the process.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of Interest Statement</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659112473172">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>S</given-names></name>
<name><surname>Holena</surname><given-names>D</given-names></name>
<name><surname>McCunn</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>A review of the fundamental principles and evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically ill adult patients</article-title>. <source>J Intensive Care Med</source> <year>2011</year>; <volume>26</volume>: <fpage>13</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr2-0267659112473172">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
<name><surname>Gattinoni</surname><given-names>L</given-names></name>
</person-group>. <article-title>Current status of extracorporeal life support (ECMO) for cardiopulmonary failure</article-title>. <source>Minerva Anestesiol</source> <year>2010</year>; <volume>76</volume>: <fpage>534</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr3-0267659112473172">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindstrom</surname><given-names>SJ</given-names></name>
<name><surname>Pellegrino</surname><given-names>VA</given-names></name>
<name><surname>Butt</surname><given-names>WW</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation</article-title>. <source>Med J Aust</source> <year>2009</year>; <volume>191</volume>: <fpage>178</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr4-0267659112473172">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>JF</given-names></name>
<name><surname>Shekar</surname><given-names>K</given-names></name>
<name><surname>Diab</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>ECMO - the clinician’s view</article-title>. <source>ISBT Sci Series</source> <year>2012</year>; <volume>7</volume>: <fpage>82</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr5-0267659112473172">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>JP</given-names></name>
<name><surname>Kon</surname><given-names>ZN</given-names></name>
<name><surname>Evans</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2011</year>; <volume>142</volume>: <fpage>755</fpage>–<lpage>761</lpage>.</citation>
</ref>
<ref id="bibr6-0267659112473172">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marasco</surname><given-names>SF</given-names></name>
<name><surname>Lukas</surname><given-names>G</given-names></name>
<name><surname>McDonald</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients</article-title>. <source>Heart Lung Circ</source> <year>2008</year>; <volume>17</volume> <supplement>Suppl 4</supplement>: <fpage>S41</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr7-0267659112473172">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stulak</surname><given-names>JM</given-names></name>
<name><surname>Dearani</surname><given-names>JA</given-names></name>
<name><surname>Burkhart</surname><given-names>HM</given-names></name>
<etal/></person-group>. <article-title>ECMO cannulation controversies and complications</article-title>. <source>Semin Cariothorac Vasc Anesth</source> <year>2009</year>; <volume>13</volume>: <fpage>176</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr8-0267659112473172">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasavada</surname><given-names>R</given-names></name>
<name><surname>Feng Qiu</surname></name>
<name><surname>Undar</surname><given-names>A</given-names></name>
</person-group>. <article-title>Current status of pediatric/neonatal extracorporeal life support: clinical outcomes, circuit evolution, and translational research</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>294</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr9-0267659112473172">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferraris</surname><given-names>VA</given-names></name>
<name><surname>Brown</surname><given-names>JR</given-names></name>
<name><surname>Despotis</surname><given-names>GJ</given-names></name>
<etal/></person-group>. <article-title>2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines</article-title>. <source>Ann Thorac Surg</source> <year>2011</year> ;<volume>91</volume>: <fpage>944</fpage>–<lpage>982</lpage>.</citation>
</ref>
<ref id="bibr10-0267659112473172">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sievert</surname><given-names>A</given-names></name>
<name><surname>Uber</surname><given-names>W</given-names></name>
<name><surname>Laws</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>59</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr11-0267659112473172">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muntean</surname><given-names>W</given-names></name>
</person-group>. <article-title>Coagulation and anticoagulation in extracorporeal membrane oxygenation</article-title>. <source>Artif Organs</source> <year>1999</year>; <volume>23</volume>: <fpage>979</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr12-0267659112473172">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klinger</surname><given-names>G</given-names></name>
<name><surname>Beyene</surname><given-names>J</given-names></name>
<name><surname>Shah</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Do hyperoxaemia and hypocapnia add to the risk of brain injury after intrapartum asphyxia?</article-title> <source>Arch Dis Child Fetal Neonatal Ed</source> <year>2005</year>; <volume>90</volume>: <fpage>F49</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr13-0267659112473172">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>DP</given-names></name>
<name><surname>Meade</surname><given-names>W</given-names></name>
<name><surname>Sise</surname><given-names>MJ</given-names></name>
<etal/></person-group>. <article-title>Both hypoxemia and extreme hyperoxemia may be detrimental in patients with severe traumatic brain injury</article-title>. <source>J Neurotrauma</source> <year>2009</year>; <volume>26</volume>: <fpage>2217</fpage>–<lpage>2223</lpage>.</citation>
</ref>
<ref id="bibr14-0267659112473172">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellomo</surname><given-names>R</given-names></name>
<name><surname>Bailey</surname><given-names>M</given-names></name>
<name><surname>Eastwood</surname><given-names>GM</given-names></name>
<etal/></person-group>. <article-title>Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest</article-title>. <source>Crit Care</source> <year>2011</year>; <volume>15</volume>: <fpage>R90</fpage>.</citation>
</ref>
<ref id="bibr15-0267659112473172">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spurlock</surname><given-names>DJ</given-names></name>
<name><surname>Toomasian</surname><given-names>JM</given-names></name>
<name><surname>Romano</surname><given-names>MA</given-names></name>
<etal/></person-group>. <article-title>A simple technique to prevent limb ischemia during veno-arterial ECMO using the femoral artery: the posterior tibial approach</article-title>. <source>Perfusion</source> <year>2012</year>; <volume>27</volume>: <fpage>141</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr16-0267659112473172">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shekar</surname><given-names>K</given-names></name>
<name><surname>Fraser</surname><given-names>JF</given-names></name>
<name><surname>Smith</surname><given-names>MT</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation</article-title>. <source>J Crit Care</source> <year>2012</year>; <volume>27</volume>: <fpage>741</fpage>.</citation>
</ref>
<ref id="bibr17-0267659112473172">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>T</given-names></name>
<name><surname>Takata</surname><given-names>M</given-names></name>
<name><surname>Arai</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>The effect of left-to-right shunting on coronary oxygenation during extracorporeal membrane oxygenation</article-title>. <source>J Pediatr Surg</source> <year>1999</year>; <volume>34</volume>: <fpage>981</fpage>–<lpage>985</lpage>.</citation>
</ref>
<ref id="bibr18-0267659112473172">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joachimsson</surname><given-names>PO</given-names></name>
<name><surname>Sjöberg</surname><given-names>F</given-names></name>
<name><surname>Forsman</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Adverse effects of hyperoxemia during cardiopulmonary bypass</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>1996</year>; <volume>112</volume>: <fpage>812</fpage>–<lpage>819</lpage>.</citation>
</ref>
<ref id="bibr19-0267659112473172">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kilgannon</surname><given-names>JH</given-names></name>
<name><surname>Jones</surname><given-names>AE</given-names></name>
<name><surname>Shapiro</surname><given-names>NI</given-names></name>
<etal/></person-group>. <article-title>Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality</article-title>. <source>JAMA</source> <year>2010</year>; <volume>303</volume>: <fpage>2165</fpage>–<lpage>2171</lpage>.</citation>
</ref>
<ref id="bibr20-0267659112473172">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsangaris</surname><given-names>H</given-names></name>
<name><surname>Pneumatikos</surname><given-names>J</given-names></name>
<name><surname>Sdranis</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>The effect of hyperoxaemia on erythropoietin secretion in anaemic patients</article-title>. <source>Monaldi Arch Chest Dis</source> <year>1999</year>; <volume>54</volume>: <fpage>120</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr21-0267659112473172">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kilgannon</surname><given-names>JH</given-names></name>
<name><surname>Jones</surname><given-names>AE</given-names></name>
<name><surname>Parrillo</surname><given-names>JE</given-names></name>
<etal/></person-group>. <article-title>Relationship between supranormal oxygen tension and outcome after resuscitation from cardiac arrest</article-title>. <source>Circulation</source> <year>2011</year>; <volume>123</volume>: <fpage>2717</fpage>–<lpage>2722</lpage>.</citation>
</ref>
<ref id="bibr22-0267659112473172">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>LP</given-names></name>
<name><surname>Durward</surname><given-names>A</given-names></name>
<name><surname>Tibby</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Relationship between arterial partial oxygen pressure after resuscitation from cardiac arrest and mortality in children</article-title>. <source>Circulation</source> <year>2012</year>; <volume>126</volume>: <fpage>335</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr23-0267659112473172">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>M</given-names></name>
<name><surname>Stein</surname><given-names>D</given-names></name>
<name><surname>Hu</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Association between early hyperoxia and worse outcomes after traumatic brain injury</article-title>. <source>Arch Surg</source> <year>2012</year>; <volume>147</volume> : <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr24-0267659112473172">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Jonge</surname><given-names>E</given-names></name>
<name><surname>Peelen</surname><given-names>L</given-names></name>
<name><surname>Keijzers</surname><given-names>PJ</given-names></name>
<etal/></person-group>. <article-title>Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients</article-title>. <source>Crit Care</source> <year>2008</year>; <volume>12</volume>: <fpage>R156</fpage>.</citation>
</ref>
<ref id="bibr25-0267659112473172">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mach</surname><given-names>WJ</given-names></name>
<name><surname>Thimmesch</surname><given-names>AR</given-names></name>
<name><surname>Pierce</surname><given-names>JT</given-names></name>
<etal/></person-group>. <article-title>Consequences of hyperoxia and the toxicity of oxygen in the lung</article-title>. <source>Nurs Res Pract</source> <year>2011</year>; <volume>2011</volume>: <fpage>260482</fpage>.</citation>
</ref>
<ref id="bibr26-0267659112473172">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartorelli</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Hyperoxemic perfusion for treatment of reperfusion microvascular ischemia in patients with myocardial infarction</article-title>. <source>Am J Cardiovasc Drugs</source> <year>2003</year>; <volume>3</volume>: <fpage>253</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr27-0267659112473172">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bigdeli</surname><given-names>MR</given-names></name>
<name><surname>Asheghabadi</surname><given-names>M</given-names></name>
<name><surname>Khalili</surname><given-names>A</given-names></name>
</person-group>. <article-title>Time course of neuroprotection induced by normobaric hyperoxia in focal cerebral ischemia</article-title>. <source>Neurol Res</source> <year>2012</year>; <volume>34</volume>: <fpage>439</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr28-0267659112473172">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Auer</surname><given-names>RN</given-names></name>
</person-group>. <article-title>Non-pharmacologic (physiologic) neuroprotection in the treatment of brain ischemia</article-title>. <source>Ann N Y Acad Sci</source> <year>2001</year>; <volume>939</volume>: <fpage>271</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr29-0267659112473172">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stub</surname><given-names>D</given-names></name>
<name><surname>Smith</surname><given-names>K</given-names></name>
<name><surname>Bernard</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>A randomized controlled trial of oxygen therapy in acute myocardial infarction Air Verses Oxygen In myocarDial infarction study (AVOID Study)</article-title>. <source>Am Heart J</source> <year>2012</year>; <volume>163</volume>: <fpage>339</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr30-0267659112473172">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyamoto</surname><given-names>O</given-names></name>
<name><surname>Auer</surname><given-names>RN</given-names></name>
</person-group>. <article-title>Hypoxia, hyperoxia, ischemia, and brain necrosis</article-title>. <source>Neurology</source> <year>2000</year>; <volume>54</volume>: <fpage>362</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr31-0267659112473172">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyhoff</surname><given-names>CS</given-names></name>
<name><surname>Staehr</surname><given-names>AK</given-names></name>
<name><surname>Rasmussen</surname><given-names>LS</given-names></name>
</person-group>. <article-title>Rational use of oxygen in medical disease and anesthesia</article-title>. <source>Curr Opin Anaesthesiol</source> <year>2012</year>; <volume>25</volume>: <fpage>363</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr32-0267659112473172">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schultz</surname><given-names>JM</given-names></name>
<name><surname>Karamlou</surname><given-names>T</given-names></name>
<name><surname>Shen</surname><given-names>I</given-names></name>
<etal/></person-group>. <article-title>Cardiac output augmentation during hypoxemia improves cerebral metabolism after hypothermic cardiopulmonary bypass</article-title>. <source>Ann Thorac Surg</source> <year>2006</year>; <volume>81</volume>: <fpage>625</fpage>–<lpage>632</lpage>; discussion 632–633.</citation>
</ref>
<ref id="bibr33-0267659112473172">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toraman</surname><given-names>F</given-names></name>
<name><surname>Evrenkaya</surname><given-names>S</given-names></name>
<name><surname>Senay</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Adjusting oxygen fraction to avoid hyperoxemia during cardiopulmonary bypass</article-title>. <source>Asian Cardiovasc Thorac Ann</source> <year>2007</year>; <volume>15</volume>: <fpage>303</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr34-0267659112473172">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>AJ</given-names></name>
<name><surname>Brand</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Reactive oxygen species production by mitochondria</article-title>. <source>Methods Mol Biol</source> <year>2009</year>; <volume>554</volume>: <fpage>165</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr35-0267659112473172">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishikawa</surname><given-names>T</given-names></name>
<name><surname>Araki</surname><given-names>E</given-names></name>
</person-group>. <article-title>Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications</article-title>. <source>Antioxid Redox Signal</source> <year>2007</year>; <volume>9</volume>: <fpage>343</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr36-0267659112473172">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ralph</surname><given-names>SJ</given-names></name>
<name><surname>Rodríguez-Enríquez</surname><given-names>S</given-names></name>
<name><surname>Neuzil</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy</article-title>. <source>Mol Aspects Med</source> <year>2010</year>; <volume>31</volume>: <fpage>145</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr37-0267659112473172">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neumar</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Optimal oxygenation during and after cardiopulmonary resuscitation</article-title>. <source>Curr Opin Crit Care</source> <year>2011</year>; <volume>17</volume>: <fpage>236</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr38-0267659112473172">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ang</surname><given-names>AL</given-names></name>
<name><surname>Teo</surname><given-names>D</given-names></name>
<name><surname>Lim</surname><given-names>CH</given-names></name>
<etal/></person-group>. <article-title>Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation – a single centre experience</article-title>. <source>Vox Sang</source> <year>2009</year>; <volume>96</volume>: <fpage>34</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr39-0267659112473172">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mangalmurti</surname><given-names>NS</given-names></name>
<name><surname>Chatterjee</surname><given-names>S</given-names></name>
<name><surname>Cheng</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products</article-title>. <source>Transfusion</source> <year>2010</year>; <volume>50</volume>: <fpage>2353</fpage>–<lpage>2361</lpage>.</citation>
</ref>
<ref id="bibr40-0267659112473172">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>CI</given-names></name>
<name><surname>Fung</surname><given-names>YL</given-names></name>
<name><surname>Fraser</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Antioxidant trace element reduction in an in vitro cardiopulmonary bypass circuit</article-title>. <source>ASAIO J</source> <year>2012</year>; <volume>58</volume>: <fpage>217</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr41-0267659112473172">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Förstermann</surname><given-names>U.</given-names></name>
</person-group> <article-title>Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies</article-title>. <source>Nat Clin Pract Cardiovasc Med</source> <year>2008</year>; <volume>5</volume>: <fpage>338</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr42-0267659112473172">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klotz</surname><given-names>LO</given-names></name>
<name><surname>Kröncke</surname><given-names>KD</given-names></name>
<name><surname>Buchczyk</surname><given-names>DP</given-names></name>
<etal/></person-group>. <article-title>Role of copper, zinc, selenium and tellurium in the cellular defense against oxidative and nitrosative stress</article-title>. <source>J Nutr</source> <year>2003</year>; <volume>133</volume>: <fpage>1448S</fpage>–<lpage>451S</lpage>.</citation>
</ref>
<ref id="bibr43-0267659112473172">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perkowski</surname><given-names>S</given-names></name>
<name><surname>Scherpereel</surname><given-names>A</given-names></name>
<name><surname>Murciano</surname><given-names>JC</given-names></name>
<etal/></person-group>. <article-title>Dissociation between alveolar transmigration of neutrophils and lung injury in hyperoxia</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <year>2006</year>; <volume>291</volume>: <fpage>L1050</fpage>–<lpage>1058</lpage>.</citation>
</ref>
<ref id="bibr44-0267659112473172">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fung</surname><given-names>YL</given-names></name>
<name><surname>Fraser</surname><given-names>JF</given-names></name>
<name><surname>Wood</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>The systemic inflammatory response syndrome induces functional changes and relative hyporesponsiveness in neutrophils</article-title>. <source>J Crit Care</source> <year>2008</year>; <volume>23</volume>: <fpage>542</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr45-0267659112473172">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciapetti</surname><given-names>M</given-names></name>
<name><surname>Cianchi</surname><given-names>G</given-names></name>
<name><surname>Zagli</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Feasibility of inter-hospital transportation using extra-corporeal membrane oxygenation (ECMO) support of patients affected by severe swine-flu(H1N1)-related ARDS</article-title>. <source>Scand J Trauma Resusc Emerg Med</source> <year>2011</year>; <volume>19</volume>: <fpage>32</fpage>.</citation>
</ref>
<ref id="bibr46-0267659112473172">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noah</surname><given-names>MA</given-names></name>
<name><surname>Peek</surname><given-names>GJ</given-names></name>
<name><surname>Finney</surname><given-names>SJ</given-names></name>
<etal/></person-group>. <article-title>Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)</article-title>. <source>JAMA</source> <year>2011</year>; <volume>306</volume>: <fpage>1659</fpage>–<lpage>1668</lpage>.</citation>
</ref>
<ref id="bibr47-0267659112473172">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaminski</surname><given-names>KA</given-names></name>
<name><surname>Bonda</surname><given-names>TA</given-names></name>
<name><surname>Korecki</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Oxidative stress and neutrophil activation–the two keystones of ischemia/reperfusion injury</article-title>. <source>Int J Cardiol</source> <year>2002</year>; <volume>86</volume>: <fpage>41</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr48-0267659112473172">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fontana</surname><given-names>L</given-names></name>
<name><surname>Giagulli</surname><given-names>C</given-names></name>
<name><surname>Minuz</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>8-Iso-PGF2 alpha induces beta 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2001</year>; <volume>21</volume>: <fpage>55</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr49-0267659112473172">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tung</surname><given-names>JP</given-names></name>
<name><surname>Fraser</surname><given-names>JF</given-names></name>
<name><surname>Wood</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Respiratory burst function of ovine neutrophils</article-title>. <source>BMC Immunol</source> <year>2009</year>; <volume>10</volume>: <fpage>25</fpage>.</citation>
</ref>
<ref id="bibr50-0267659112473172">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Basili</surname><given-names>S</given-names></name>
<name><surname>Pignatelli</surname><given-names>P</given-names></name>
<name><surname>Tanzilli</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2011</year>; <volume>31</volume>: <fpage>1766</fpage>–<lpage>1771</lpage>.</citation>
</ref>
<ref id="bibr51-0267659112473172">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Biase</surname><given-names>L</given-names></name>
<name><surname>Pignatelli</surname><given-names>P</given-names></name>
<name><surname>Lenti</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O<sub>2</sub>- production</article-title>. <source>Thromb Haemost</source> <year>2003</year>; <volume>90</volume>: <fpage>317</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr52-0267659112473172">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adrian</surname><given-names>K</given-names></name>
<name><surname>Mellgren</surname><given-names>K</given-names></name>
<name><surname>Skogby</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Cytokine release during long-term extracorporeal circulation in an experimental model</article-title>. <source>Artif Organs</source> <year>1998</year>; <volume>22</volume>: <fpage>859</fpage>–<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr53-0267659112473172">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fortenberry</surname><given-names>JD</given-names></name>
<name><surname>Bhardwaj</surname><given-names>V</given-names></name>
<name><surname>Niemer</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation</article-title>. <source>J Pediatr</source> <year>1996</year>; <volume>128</volume>: <fpage>670</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr54-0267659112473172">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schaible</surname><given-names>T</given-names></name>
<name><surname>Veit</surname><given-names>M</given-names></name>
<name><surname>Tautz</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Serum cytokine levels in neonates with congenital diaphragmatic hernia</article-title>. <source>Klin Pädiatr</source> <year>2011</year>; <volume>223</volume>: <fpage>414</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr55-0267659112473172">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McIlwain</surname><given-names>RB</given-names></name>
<name><surname>Timpa</surname><given-names>JG</given-names></name>
<name><surname>Kurundkar</surname><given-names>AR</given-names></name>
<etal/></person-group>. <article-title>Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine</article-title>. <source>Lab Invest</source> <year>2010</year>; <volume>90</volume>: <fpage>128</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr56-0267659112473172">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caudrillier</surname><given-names>A</given-names></name>
<name><surname>Kessenbrock</surname><given-names>K</given-names></name>
<name><surname>Gilliss</surname><given-names>BM</given-names></name>
<etal/></person-group>. <article-title>Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury</article-title>. <source>J Clin Invest</source> <year>2012</year>; <volume>122</volume>: <fpage>2661</fpage>–<lpage>2671</lpage>.</citation>
</ref>
<ref id="bibr57-0267659112473172">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caudrillier</surname><given-names>A</given-names></name>
<name><surname>Looney</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury</article-title>. <source>Curr Pharm Des</source> <year>2012</year>; <volume>18</volume>: <fpage>3260</fpage>–<lpage>3266</lpage>.</citation>
</ref>
<ref id="bibr58-0267659112473172">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Begonja</surname><given-names>AJ</given-names></name>
<name><surname>Gambaryan</surname><given-names>S</given-names></name>
<name><surname>Geiger</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway</article-title>. <source>Blood</source> <year>2005</year>; <volume>106</volume>: <fpage>2757</fpage>–<lpage>2760</lpage>.</citation>
</ref>
<ref id="bibr59-0267659112473172">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chlopicki</surname><given-names>S</given-names></name>
<name><surname>Olszanecki</surname><given-names>R</given-names></name>
<name><surname>Janiszewski</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Functional role of NADPH oxidase in activation of platelets</article-title>. <source>Antioxid Redox Signal</source> <year>2004</year>; <volume>6</volume>: <fpage>691</fpage>–<lpage>698</lpage>.</citation>
</ref>
<ref id="bibr60-0267659112473172">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arita</surname><given-names>H</given-names></name>
<name><surname>Nakano</surname><given-names>T</given-names></name>
<name><surname>Hanasaki</surname><given-names>K</given-names></name>
</person-group>. <article-title>Thromboxane A2: its generation and role in platelet activation</article-title>. <source>Prog Lipid Res</source> <year>1989</year>; <volume>28</volume>: <fpage>273</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr61-0267659112473172">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olas</surname><given-names>B</given-names></name>
<name><surname>Wachowicz</surname><given-names>B</given-names></name>
</person-group>. <article-title>Role of reactive nitrogen species in blood platelet functions</article-title>. <source>Platelets</source> <year>2007</year>; <volume>18</volume>: <fpage>555</fpage>–<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr62-0267659112473172">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Oxidative stress and platelets</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2008</year>; <volume>28</volume>: <fpage>s11</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr63-0267659112473172">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iuliano</surname><given-names>L</given-names></name>
<name><surname>Colavita</surname><given-names>AR</given-names></name>
<name><surname>Leo</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Oxygen free radicals and platelet activation</article-title>. <source>Free Radic Biol Med</source> <year>1997</year>; <volume>22</volume>: <fpage>999</fpage>–<lpage>1006</lpage>.</citation>
</ref>
<ref id="bibr64-0267659112473172">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michelson</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Methods for the measurement of platelet function</article-title>. <source>Am J Cardiol</source> <year>2009</year>; <volume>103</volume>: <fpage>20A</fpage>–<lpage>26A</lpage>.</citation>
</ref>
<ref id="bibr65-0267659112473172">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>C</given-names></name>
<name><surname>Ye</surname><given-names>F</given-names></name>
<name><surname>Ginsberg</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Regulation of integrin activation</article-title>. <source>Ann Rev Cell Dev Biol</source> <year>2011</year>; <volume>27</volume>: <fpage>321</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr66-0267659112473172">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Offermanns</surname><given-names>S</given-names></name>
</person-group>. <article-title>Activation of platelet function through G protein-coupled receptors</article-title>. <source>Circ Res</source> <year>2006</year>; <volume>99</volume>: <fpage>1293</fpage>–<lpage>1304</lpage>.</citation>
</ref>
<ref id="bibr67-0267659112473172">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smyth</surname><given-names>SS</given-names></name>
<name><surname>McEver</surname><given-names>RP</given-names></name>
<name><surname>Weyrich</surname><given-names>AS</given-names></name>
<etal/></person-group>. <article-title>Platelet functions beyond hemostasis</article-title>. <source>J Thromb Haemost</source> <year>2009</year>; <volume>7</volume>: <fpage>1759</fpage>–<lpage>1766</lpage>.</citation>
</ref>
<ref id="bibr68-0267659112473172">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazar</surname><given-names>DA</given-names></name>
<name><surname>Cass</surname><given-names>DL</given-names></name>
<name><surname>Olutoye</surname><given-names>OO</given-names></name>
<etal/></person-group>. <article-title>Venovenous cannulation for extracorporeal membrane oxygenation using a bicaval dual-lumen catheter in neonates</article-title>. <source>J Pediatr Surg</source> <year>2012</year>; <volume>47</volume>: <fpage>430</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr69-0267659112473172">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>J</given-names></name>
</person-group>. <article-title>Nitric oxide: platelet protectant properties during cardiopulmonary bypass/ECMO</article-title>. <source>J Extra Corpor Technol</source> <year>2002</year>; <volume>34</volume>: <fpage>144</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr70-0267659112473172">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frenckner</surname><given-names>B</given-names></name>
<name><surname>Radell</surname><given-names>P</given-names></name>
</person-group>. <article-title>Respiratory failure and extracorporeal membrane oxygenation</article-title>. <source>Semin Pediatr Surg</source> <year>2008</year>; <volume>17</volume>: <fpage>34</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr71-0267659112473172">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Konkle</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Acquired disorders of platelet function</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <year>2011</year>; <volume>2011</volume>: <fpage>391</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr72-0267659112473172">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samama</surname><given-names>CM</given-names></name>
<name><surname>Diaby</surname><given-names>M</given-names></name>
<name><surname>Fellahi</surname><given-names>JL</given-names></name>
<etal/></person-group>. <article-title>Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome</article-title>. <source>Anesthesiology</source> <year>1995</year>; <volume>83</volume>: <fpage>56</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr73-0267659112473172">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowson</surname><given-names>SM</given-names></name>
<name><surname>Hassan</surname><given-names>HM</given-names></name>
<name><surname>Rich</surname><given-names>GF</given-names></name>
</person-group>. <article-title>The effect of nitric oxide on platelets when delivered to the cardiopulmonary bypass circuit</article-title>. <source>Anesth Analg</source> <year>1999</year>; <volume>89</volume>: <fpage>1360</fpage>–<lpage>1365</lpage>.</citation>
</ref>
<ref id="bibr74-0267659112473172">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rauch</surname><given-names>ED</given-names></name>
<name><surname>Stammers</surname><given-names>AH</given-names></name>
<name><surname>Mejak</surname><given-names>BL</given-names></name>
<etal/></person-group>. <article-title>The effects of nitric oxide on coagulation during simulated extracorporeal membrane oxygenation</article-title>. <source>J Extra Corpor Technol</source> <year>2000</year>; <volume>32</volume>: <fpage>214</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr75-0267659112473172">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Afshari</surname><given-names>A</given-names></name>
<name><surname>Brok</surname><given-names>J</given-names></name>
<name><surname>Møller</surname><given-names>AM</given-names></name>
<etal/></person-group>. <article-title>Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults</article-title>. <source>Cochrane Database Syst Rev</source> <year>2010</year>; CD002787.</citation>
</ref>
<ref id="bibr76-0267659112473172">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adhikari</surname><given-names>NK</given-names></name>
<name><surname>Burns</surname><given-names>KE</given-names></name>
<name><surname>Friedrich</surname><given-names>JO</given-names></name>
<etal/></person-group>. <article-title>Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis</article-title>. <source>BMJ</source> <year>2007</year>; <volume>334</volume>: <fpage>779</fpage>.</citation>
</ref>
<ref id="bibr77-0267659112473172">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forceville</surname><given-names>X</given-names></name>
<name><surname>Vitoux</surname><given-names>D</given-names></name>
<name><surname>Gauzit</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients</article-title>. <source>Crit Care Med</source> <year>1998</year>; <volume>26</volume>: <fpage>1536</fpage>–<lpage>1544</lpage>.</citation>
</ref>
<ref id="bibr78-0267659112473172">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>GL</given-names></name>
<name><surname>McKinzie</surname><given-names>BP</given-names></name>
<name><surname>Bullington</surname><given-names>WM</given-names></name>
<etal/></person-group>. <article-title>Nutritional supplements in critical illness</article-title>. <source>AACN Adv Crit Care</source> <year>2011</year>; <volume>22</volume>: <fpage>301</fpage>–<lpage>316</lpage>; quiz 317–318.</citation>
</ref>
<ref id="bibr79-0267659112473172">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sadowska</surname><given-names>AM</given-names></name>
<name><surname>Manuel-Y-Keenoy</surname><given-names>B</given-names></name>
<name><surname>De Backer</surname><given-names>WA</given-names></name>
</person-group>. <article-title>Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review</article-title>. <source>Pulm Pharmacol Ther</source> <year>2007</year>; <volume>20</volume>: <fpage>9</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr80-0267659112473172">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allegra</surname><given-names>L</given-names></name>
<name><surname>Dal Sasso</surname><given-names>M</given-names></name>
<name><surname>Bovio</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations</article-title>. <source>Arzneimittelforschung</source> <year>2002</year>; <volume>52</volume>: <fpage>669</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr81-0267659112473172">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buyukhatipoglu</surname><given-names>H</given-names></name>
<name><surname>Sezen</surname><given-names>Y</given-names></name>
<name><surname>Yildiz</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions</article-title>. <source>Pol Arch Med Wewn</source> <year>2010</year>; <volume>120</volume>: <fpage>383</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr82-0267659112473172">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adabag</surname><given-names>AS</given-names></name>
<name><surname>Ishani</surname><given-names>A</given-names></name>
<name><surname>Bloomfield</surname><given-names>HE</given-names></name>
<etal/></person-group>. <article-title>Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>1910</fpage>–<lpage>1917</lpage>.</citation>
</ref>
<ref id="bibr83-0267659112473172">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akca</surname><given-names>S</given-names></name>
<name><surname>Haji-Michael</surname><given-names>P</given-names></name>
<name><surname>De Mendonça</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Time course of platelet counts in critically ill patients</article-title>. <source>Crit Care Med</source> <year>2002</year>; <volume>30</volume>: <fpage>753</fpage>–<lpage>756</lpage>.</citation>
</ref>
<ref id="bibr84-0267659112473172">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>TC</given-names></name>
<name><surname>Carcillo</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Bench-to-bedside review: thrombocytopenia-associated multiple organ failure–a newly appreciated syndrome in the critically ill</article-title>. <source>Critical care</source> <year>2006</year>; <volume>10</volume>: <fpage>235</fpage>.</citation>
</ref>
<ref id="bibr85-0267659112473172">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>LC</given-names></name>
</person-group>. <article-title>Heparin-coated cardiopulmonary bypass circuits: current status</article-title>. <source>Perfusion</source> <year>2001</year>; <volume>16</volume>: <fpage>417</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr86-0267659112473172">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gourlay</surname><given-names>T</given-names></name>
</person-group>. <article-title>Biomaterial development for cardiopulmonary bypass</article-title>. <source>Perfusion</source> <year>2001</year>; <volume>16</volume>: <fpage>381</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr87-0267659112473172">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shafii</surname><given-names>AE</given-names></name>
<name><surname>Brown</surname><given-names>CR</given-names></name>
<name><surname>Murthy</surname><given-names>SC</given-names></name>
<etal/></person-group>. <article-title>High incidence of upper-extremity deep vein thrombosis with dual-lumen venovenous extracorporeal membrane oxygenation</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2012</year>; <volume>144</volume>: <fpage>988</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr88-0267659112473172">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>AD</given-names></name>
<name><surname>Wiles</surname><given-names>AA</given-names></name>
<name><surname>Rivera</surname><given-names>O</given-names></name>
<etal/></person-group>. <article-title>Hemolytic and thrombocytopathic characteristics of extracorporeal membrane oxygenation systems at simulated flow rate for neonates</article-title>. <source>Pediatr Crit Care Med</source> <year>2012</year>; <volume>13</volume>: <fpage>e255</fpage>–<lpage>e261</lpage>.</citation>
</ref>
<ref id="bibr89-0267659112473172">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toomasian</surname><given-names>JM</given-names></name>
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Hemolysis and ECMO pumps in the 21st Century</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>5</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr90-0267659112473172">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shekar</surname><given-names>K</given-names></name>
<name><surname>Fung</surname><given-names>YL</given-names></name>
<name><surname>Diab</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions</article-title>. <source>Critical Care Resusc</source> <year>2012</year>; <volume>14</volume>: <fpage>105</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr91-0267659112473172">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fung</surname><given-names>YL</given-names></name>
<name><surname>Diab</surname><given-names>S</given-names></name>
<name><surname>Dunster</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Extracorporeal lessons from sheep</article-title>. <source>ISBT Sci Series</source> <year>2012</year>; <volume>7</volume>: <fpage>92</fpage>–<lpage>95</lpage>.</citation>
</ref></ref-list>
</back>
</article>